Giovanni Goggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giovanni Goggi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth M. Battinelli
Mass General Brigham Division of Classical Hematology, Harvard Medical School, Boston, MA, USA
22 shared publications - Ana Christina Garrido-Castro
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA
21 shared publications - Deepa Gautam
Brigham and Women’s Hospital 1 Division of Hematology, Department of Medicine Boston, Massachusetts
21 shared publications - Emily M. Clarke
Brigham and Women’s Hospital 1 Division of Hematology, Department of Medicine Boston, Massachusetts
21 shared publications - Grace C. Petrarca
Brigham and Women’s Hospital 1 Division of Hematology, Department of Medicine Boston, Massachusetts
21 shared publications - Harvey G. Roweth
Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
21 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Combination of RB40.34 + anti-PD-1 results in response to treatment in TNBC.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Combination of RB40.34 + anti-PD-1 results in response to treatment in TNBC.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Gating strategies used to identify different T cell types in mouse
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Gating strategies used to identify different T cell types in mouse
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse T-cell exhaustion flow panel
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse T-cell exhaustion flow panel
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
PSGL-1 blockade produces similar protective effects against exhaustion in CD4+ and CD8+ effector T cells as P-selectin inhibition
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
PSGL-1 blockade produces similar protective effects against exhaustion in CD4+ and CD8+ effector T cells as P-selectin inhibition
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector T cells in human. A, Schematic of the T-cell isolation and platelet coculture experiment. SF RPMI, serum-free RPMI. Flow cytometry was used to quantify functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells in the coculture. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector T cells in human. A, Schematic of the T-cell isolation and platelet coculture experiment. SF RPMI, serum-free RPMI. Flow cytometry was used to quantify functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells in the coculture. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse CRP-activated KO-P-selectin activated platelets do not affect CD4+ and CD8+ Effector T cells
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse CRP-activated KO-P-selectin activated platelets do not affect CD4+ and CD8+ Effector T cells
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector mouse T cells. A, Schematic of the T-cell isolation and platelet coculture experiment. Flow cytometry was used to quantify the functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells. SF RPMI, serum-free RPMI. F, Schematic of the T-cell and AT-3 coculture experiment. Levels of Zombie NIR caspase 3/7 dye detected over 48 hours. Flow cytometry to detect death in (G) CD3+ T cells and (H) AT-3 tumor cells. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector mouse T cells. A, Schematic of the T-cell isolation and platelet coculture experiment. Flow cytometry was used to quantify the functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells. SF RPMI, serum-free RPMI. F, Schematic of the T-cell and AT-3 coculture experiment. Levels of Zombie NIR caspase 3/7 dye detected over 48 hours. Flow cytometry to detect death in (G) CD3+ T cells and (H) AT-3 tumor cells. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Retained functionality in human CD4+ and CD8+ effector T cells exhausted by mTNBC platelets through introduction of crizanlizumab. A, Schematic of the platelet isolation and T-cell coculture experiment using platelets from healthy donors and patients with mTNBC. SF RPMI, serum-free RPMI. Flow cytometric analysis showing fold change (FC) in (B) CD4+ T-cell function, (C) CD8+ T-cell function, (D) CD4+ T-cell exhaustion, and (E) CD8+ T-cell exhaustion. For each panel, the FC is calculated relative to T cells cultured alone or relative to T cells cultured with mTNBC platelets, as indicated. Each data point represents one biological sample (n = 10 patients). FC values are normalized to the respective control (baseline = 1). Statistical significance was assessed using paired one-sample t tests and Wilcoxon signed-rank tests, as appropriate. Error bars represent mean ± SD. ns, not statistically significant; **, P < 0.01; ****, P < 0.0001.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Retained functionality in human CD4+ and CD8+ effector T cells exhausted by mTNBC platelets through introduction of crizanlizumab. A, Schematic of the platelet isolation and T-cell coculture experiment using platelets from healthy donors and patients with mTNBC. SF RPMI, serum-free RPMI. Flow cytometric analysis showing fold change (FC) in (B) CD4+ T-cell function, (C) CD8+ T-cell function, (D) CD4+ T-cell exhaustion, and (E) CD8+ T-cell exhaustion. For each panel, the FC is calculated relative to T cells cultured alone or relative to T cells cultured with mTNBC platelets, as indicated. Each data point represents one biological sample (n = 10 patients). FC values are normalized to the respective control (baseline = 1). Statistical significance was assessed using paired one-sample t tests and Wilcoxon signed-rank tests, as appropriate. Error bars represent mean ± SD. ns, not statistically significant; **, P < 0.01; ****, P < 0.0001.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
AT-3 injected mouse tumor data
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
AT-3 injected mouse tumor data